Interleukin-17 and transplant immunology: clinical evidence from hematopoietic cell transplantation.

IF 3.7 3区医学 Q2 IMMUNOLOGY

Expert Review of Clinical Immunology Pub Date : 2025-10-14 DOI:10.1080/1744666X.2025.2575450

J Luis Espinoza, Do Tung Dac, Nguyen Hoang Thao Giang, Akiyoshi Takami

{"title":"Interleukin-17 and transplant immunology: clinical evidence from hematopoietic cell transplantation.","authors":"J Luis Espinoza, Do Tung Dac, Nguyen Hoang Thao Giang, Akiyoshi Takami","doi":"10.1080/1744666X.2025.2575450","DOIUrl":null,"url":null,"abstract":"Introduction: Interleukin-17 (IL-17), a proinflammatory cytokine primarily produced by Th17 cells, plays a complex role in transplant immunology. Its involvement in graft-versus-host disease (GvHD) and immune regulation following hematopoietic cell transplantation (HCT) has garnered significant clinical interest, though findings remain inconsistent.Areas covered: This narrative review summarizes clinical studies in human HCT recipients investigating IL-17 cytokine levels, Th17 cell activity, and IL-17 gene polymorphisms associated with transplant outcomes. While several studies report associations between elevated IL-17 or Th17 levels and increased GvHD risk, results vary widely due to differences in study design, patient populations, and measurement methods.Expert opinion: IL-17 is a promising, though context-dependent, biomarker and therapeutic target in HCT. Its dual roles in promoting inflammation and supporting antimicrobial defense complicate therapeutic modulation. Future studies should focus on standardized assays, multi-omics approaches, and longitudinal designs to clarify its clinical utility. Tailored strategies that modulate IL-17 without impairing immune reconstitution or graft-versus-leukemia effects are likely to guide future interventions.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2025-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Clinical Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1744666X.2025.2575450","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Interleukin-17 (IL-17), a proinflammatory cytokine primarily produced by Th17 cells, plays a complex role in transplant immunology. Its involvement in graft-versus-host disease (GvHD) and immune regulation following hematopoietic cell transplantation (HCT) has garnered significant clinical interest, though findings remain inconsistent.

Areas covered: This narrative review summarizes clinical studies in human HCT recipients investigating IL-17 cytokine levels, Th17 cell activity, and IL-17 gene polymorphisms associated with transplant outcomes. While several studies report associations between elevated IL-17 or Th17 levels and increased GvHD risk, results vary widely due to differences in study design, patient populations, and measurement methods.

Expert opinion: IL-17 is a promising, though context-dependent, biomarker and therapeutic target in HCT. Its dual roles in promoting inflammation and supporting antimicrobial defense complicate therapeutic modulation. Future studies should focus on standardized assays, multi-omics approaches, and longitudinal designs to clarify its clinical utility. Tailored strategies that modulate IL-17 without impairing immune reconstitution or graft-versus-leukemia effects are likely to guide future interventions.

查看原文本刊更多论文

白细胞介素-17与移植免疫学：来自造血细胞移植的临床证据。

白细胞介素-17 （IL-17）是一种主要由Th17细胞产生的促炎细胞因子，在移植免疫中起着复杂的作用。它参与移植物抗宿主病（GvHD）和造血细胞移植（HCT）后的免疫调节已经引起了重大的临床兴趣，尽管研究结果仍然不一致。涵盖领域：本文综述了人类HCT受者的临床研究，研究IL-17细胞因子水平、Th17细胞活性和IL-17基因多态性与移植结果的关系。虽然有几项研究报告了IL-17或Th17水平升高与GvHD风险增加之间的关联，但由于研究设计、患者群体和测量方法的差异，结果差异很大。专家意见：IL-17在HCT中是一个很有前途的生物标志物和治疗靶点，尽管它依赖于环境。其促进炎症和支持抗菌防御的双重作用使治疗调节复杂化。未来的研究应集中在标准化分析、多组学方法和纵向设计上，以阐明其临床应用。调整IL-17而不损害免疫重建或移植物抗白血病效应的量身定制策略可能指导未来的干预措施。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Clinical Immunology IMMUNOLOGY-

CiteScore

7.60

自引率

2.30%

发文量

221

审稿时长

6-12 weeks

期刊介绍： Expert Review of Clinical Immunology (ISSN 1744-666X) provides expert analysis and commentary regarding the performance of new therapeutic and diagnostic modalities in clinical immunology. Members of the International Editorial Advisory Panel of Expert Review of Clinical Immunology are the forefront of their area of expertise. This panel works with our dedicated editorial team to identify the most important and topical review themes and the corresponding expert(s) most appropriate to provide commentary and analysis. All articles are subject to rigorous peer-review, and the finished reviews provide an essential contribution to decision-making in clinical immunology. Articles focus on the following key areas: • Therapeutic overviews of specific immunologic disorders highlighting optimal therapy and prospects for new medicines • Performance and benefits of newly approved therapeutic agents • New diagnostic approaches • Screening and patient stratification • Pharmacoeconomic studies • New therapeutic indications for existing therapies • Adverse effects, occurrence and reduction • Prospects for medicines in late-stage trials approaching regulatory approval • Novel treatment strategies • Epidemiological studies • Commentary and comparison of treatment guidelines Topics include infection and immunity, inflammation, host defense mechanisms, congenital and acquired immunodeficiencies, anaphylaxis and allergy, systemic immune diseases, organ-specific inflammatory diseases, transplantation immunology, endocrinology and diabetes, cancer immunology, neuroimmunology and hematological diseases.